

RESEARCH

Open Access

Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts

Habtom H Habte¹, Corena de Beer², Zoë E Lotz¹, Paul Roux³, Anwar S Mall^{1*}

Abstract

Background: We have previously shown that MUC5B and MUC7 mucins from saliva of HIV negative individuals inhibit HIV-1 activity by 100% in an *in vitro* assay. The purpose of this subsequent study was to investigate whether MUC5B and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory activity against the virus.

Methods: Salivary MUC5B and MUC7 from HIV patients with different CD4 counts (< 200, 200-400 and > 400) were incubated with HIV-1 prior to infection of the human T lymphoblastoid cell line (CEM SS cells). Cells were then cultured and viral replication was measured by a qualitative p24 antigen assay. The size, charge and immunoreactivity of mucins from HIV negative and positive individuals was also analysed by SDS-PAGE, Western blot and ELISA respectively.

Results: It was shown that irrespective of their CD4 counts both MUC5B and MUC7 from HIV patients, unlike the MUC5B and MUC7 from HIV negative individuals, did not inhibit HIV-1 activity. Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by SDS-PAGE, Western blot and ELISA.

Conclusions: Purified salivary mucins from HIV positive patients do not inhibit the AIDS virus in an *in vitro* assay. Although the reason for the inability of mucins from infected individuals to inhibit the virus is not known, it is likely that there is an alteration of the glycosylation pattern, and therefore of charge of mucin, in HIV positive patients. The ability to inhibit the virus by aggregation by sugar chains is thus diminished.

Background

Several *in vitro* studies have shown that human saliva inhibits the activity of Human Immunodeficiency Virus (HIV) [1-3] the causative agent of Acquired Immunodeficiency Syndrome (AIDS). We hypothesized and confirmed that salivary MUC5B and MUC7 [4], breast milk mucin (MUC1) [5] and cervical or pregnancy plug mucins [6] inhibited HIV-1 activity in an *in vitro* inhibition assay. We have also shown the inhibition of poxvirus activity by MUC1 [7]. With this in mind, we decided to investigate whether MUC5B and MUC7 from saliva of HIV patients or with full blown AIDS had a similar inhibitory activity, as the MUC5B and MUC7 from HIV negative individuals [4], against the virus. Although there

have been documented cases of transmission of HIV through the exchange of oral fluids, this is indeed very rare and confined to a small group of those with ulcerations or injuries to the mucosal lining of the mouth (personal communication, David Coetzee, UCT).

In this assay a subtype D HIV-1 virus which was first isolated in February 1988 from an AIDS patient and characterised by the Department of Medical Virology, Tygerberg Hospital, Cape Town, South Africa, was used. Incubation of the virus with CEM-SS cells which expresses CD4, CXCR4, ICAM-3 and MHC class II molecules [8] results in the latter forming syncytia upon infection [9].

Results

Mucin preparation, purification, identification and analysis

As described by Habte *et al.* [4], the SDS-PAGE band appearance, Western blotting and amino acid analysis

* Correspondence: anwar.mall@uct.ac.za

¹Department of Surgery, Division of General Surgery, University of Cape Town, Observatory, Cape 7925, South Africa

Full list of author information is available at the end of the article

have shown the salivary mucins which eluted in the void and included volumes of the Sepharose CL-4B gel filtration column to be MUC5B and MUC7 respectively.

Toxicity assay

Prior to the inhibition assay, the toxicity of salivary MUC5B and MUC7 mucins from HIV patients with CD4 count (< 200, 200-400 and > 400) to the CEM SS cells was determined by toxicity assay. As shown in Table 1, there was death of 5% of the cells when incubated with MUC5B from patients with CD4 count 200-400. Other than that, there was no toxic effect of any mucin to the CEM SS cells.

Inhibition assay

To check whether the salivary MUC5B and MUC7 mucins from HIV patients possess the same inhibitory activity as those from HIV negative individuals [4], the anti-HIV-1 activities of the salivary MUC5B and MUC7 mucins from the three groups of HIV patients (i.e. patients with CD count < 200, 200-400 and > 400) was determined in an *in vitro* inhibition assay. The result demonstrated that irrespective of their CD4 count both MUC5B and MUC7 mucins from HIV patients, unlike those HIV negative patients, failed to inhibit HIV-1 activity and a 100% viral infection of the CEM SS cells was measured by the p24 antigen assay after a 30 min incubation period (Figure 1A-C). This was unlike MUC5B and MUC7 mucins from HIV negative individuals [4]. When HIV-1 was treated with the media instead of mucins as a control, 100% HIV-1 replication or infection of the CEM SS cells was detected (Figure 1A, B and 1C). However, no HIV-1 infection was seen when heat inactivated HIV-1 was used (Figure 1A, B and 1C).

The effect of the length of the incubation period on the rate of inhibition of the HIV-1 infection of the CEM

SS cells was determined by incubating the CEM SS cells with the mixtures for 1 h and 2 h. There was no difference due to the length of the incubation period (Figure 1A, B and 1C). As in the case of the MUC5B and MUC7 from HIV negative individuals [4], serial tenfold dilution, (10^{-1} to 10^{-4}) of the MUC5B and MUC7 mucins, starting at 0.9 mg mucin, from HIV patients of all the different CD4 counts (< 200, 200-400 and > 400) were done in triplicate and this made no difference to infectivity (data not shown).

To determine if the salivary MUC5B and MUC7 mucins from HIV positive patients trap or aggregate the viruses as the MUC5B and MUC7 mucins from HIV negative individuals did [4] the mixtures were filtered through 0.45 μ m pore size cellulose acetate filter at the end of the incubation period (60 min), and the filtrates were subsequently incubated with the CEM SS cells for 30 min. Unlike the filtrates from the mixtures of HIV-1 plus MUC5B and MUC7 from HIV negative individuals [4], these filtrates caused 100% viral infection of the CEM SS cells (Figure 2A, B and 2C). Even if these filtrates were incubated with the CEM SS cells for 1 h and 2 h, no change from the above results was observed (Figure 2A, B and 2C).

Gradient gel analyses

To assess if the HIV infection induced any structural or size difference on the salivary MUC5B and MUC7 mucins, salivary MUC5B and MUC7 mucins from HIV positive individuals with different CD4 counts (< 200, 200-400 and > 400), were dissolved in a gel loading buffer and were subjected to a 4-20% gradient gel alongside the salivary MUC5B and MUC7 mucins from HIV negative individuals as a control (Figure 3).

The PAS stained gel showed that the MUC5B from normals had slightly more material in the stacking gel and less penetration into the running gel (lane 1) than that from the HIV patients with CD4 count < 200 (lane 2), 200-400 (lane 3) and > 400 (lane 4) which showed less material in the stacking gel and high penetration into the running gel. MUC5B from patients with CD4 count < 200 (lane 2) appeared as a broader band on the top of the running gel. The MUC7a from normals had slightly more material and showed less penetration into the running gel (lane 5) than that from the HIV patients with CD4 count < 200 (lane 6), 200-400 (lane 7) and > 400 (lane 8) which showed slightly less material of MUC7a and more material of MUC7b than the normal. The MUC7a from patients with CD4 count > 400 (lane 8) showed less material than the rest.


Immunoreactivity analyses

To determine if there are any immunoreactivity differences between salivary MUC5B and MUC7 mucins

Table 1 Mucin toxicity


Sample	Con	CEM SS cells	% of dead cells	% of live cells
MUC5B CD4 < 200	0.9 mg	2.5×10^6 /ml	0	100
MUC5B CD4 < 200-400	0.9 mg	2.5×10^6 /ml	5	95
MUC5B CD4 < 400	0.9 mg	2.5×10^6 /ml	0	100
MUC7 CD4 < 200	0.9 mg	2.5×10^6 /ml	0	100
MUC7 CD4 < 200-400	0.9 mg	2.5×10^6 /ml	0	100
MUC7 CD4 < 400	0.9 mg	2.5×10^6 /ml	0	100

Toxicity of salivary MUC5B and MUC7 mucins from HIV patients with CD4 count (< 200, 200-400 and > 400) to the CEM SS cells.



from HIV negative and HIV positive individuals towards the same antibodies as the result of the HIV infection, salivary MUC5B and MUC7 mucins from HIV positive individuals with different CD4 counts (< 200, 200-400 and > 400) were coated in an ELISA plate alongside the salivary MUC5B and MUC7 from HIV negative individuals and probed with anti-MUC5B and anti-MUC7 polyclonal antibodies (Figure 4).

Although the difference in immunoreactivity between mucins from HIV negative and positive samples is very small, MUC5B (Figure 4A) and MUC7 (Figure 4B) from HIV negative individuals have shown the highest reactivity towards their respective antibodies. Interestingly, we detected immunoreactivity differences between the mucins from HIV patients of different CD4 counts as well. However, none of these differences were significant.




Western blotting analyses

To determine if there are any charge differences between the salivary MUC5B and MUC7 mucins from HIV negative and HIV positive individuals or among the mucins from HIV patients of different CD4 counts, MUC5B and MUC7 mucins from HIV positive individuals with different CD4 counts (< 200, 200-400 and > 400) were run in an agarose gel alongside the MUC5B and MUC7 from HIV negative individuals as a control. Mucins were then transferred to nitrocellulose membranes and probed with polyclonal rabbit anti-MUC5B and monoclonal mouse anti-MUC7 antibodies (Figure 5).

The MUC5B from HIV negative individual (lane 4) clearly had more material and a wide range of charge after equal loading, than the MUC5B from the HIV positive patients with CD4 count > 400 (lane 1), 200-400 (lane 2) and < 200 (lane 3) which showed a relatively small range of charge. The mobilities between groups hardly differed (lanes 1-5).

Differences in the charge was observed between the MUC7 from HIV negative and HIV positive individuals and within the group of HIV patients of different CD4 counts (lanes 7-10). MUC7 from HIV negative individuals (lane 10) was of lower charge than the MUC7




from HIV positive patients with CD4 count > 400 (lane 7), 200-400 (lane 8) and < 200 (lane 9). As shown in the figure, the crude saliva positive controls reacted with the anti-MUC5B and anti-MUC7 antibodies (lanes 5 and 11) as expected, whilst the negative control for MUC7 (lane 6) and for MUC5B (lane 12) did not react with the anti-MUC5B and anti-MUC7 antibodies respectively.

Discussion

Although HIV-1 subtype C is currently the most prevalent in South Africa, the subtype D virus used in this study was found during the early stages of the HIV epidemic and is currently prevalent here, albeit less frequently. This subtype D virus is the only lab adapted strain we had available to us in the vicinity of Cape Town, in possibly the only laboratory based HIV assay in the country. The CEM-SS cells, which were used in this experiment, are known to produce distinct and repeatable syncytia formation when infected with HIV-1. These cells are capable of developing easily quantifiable syncytia formation in four to six days upon the addition of HIV-1 [9] and are reported to express CD4, CXCR4, ICAM-3 and MHC class II molecules [8], and thus could be considered a suitable model as HIV-1 host cells.

Previously we have shown that salivary MUC5B and MUC7 mucins from HIV negative individuals inhibited HIV-1 activity by 100% [4]. Here we investigated whether salivary MUC5B and MUC7 from HIV positive



individuals would have a similar inhibitory effect to that from HIV negative individuals in an *in vitro* inhibitory assay. We have shown that irrespective of their CD4 count (< 200, 200-400 and > 400) both MUC5B and MUC7 mucins from HIV patients failed to inhibit HIV-1 activity. There was a 100% infection of the CEM SS cells as detected by the p24 antigen assay. Although the reason is not clear, it is possible that HIV infection induces changes of the salivary glands which results in a decline in the amount of saliva and a change in its constituents [10]. This in turn may affect the glycosylation pattern or sugar composition of the salivary mucins, and if inhibition of the virus is through aggregation by the

carbohydrate side chains, and if changes in these sugar side chains occurs as a result of infection [11], it is conceivable that this is the reason for the inability of mucins from HIV positive individuals to inhibit the virus in an *in vitro* assay. Furthermore HIV infection is also reported to suppress the production of saliva inhibitory factors, or elicit blocking molecules [12]. Mucins are also reported to lose their carbohydrate side chains as a result of infections which could affect their ability to adhere or recognize antigens or micro-organisms [13]. Thus there is a higher possibility that the HIV infection induced change in the glycosylation pattern of the mucins.

To check whether the HIV infection affected the ability of the mucins to trap or aggregate the virus, the filtrates of the mixtures were incubated with the CEM SS cells. The filtrates caused 100% infection of the CEM SS cells, unlike the filtrates from the mixtures of HIV-1 and normal mucins [4]. This suggests that both MUC5B and MUC7 mucins from HIV positive individuals, irrespective of their CD4 count failed to aggregate the virus. Hence there were free viruses in the filtrates that could enter the CEM SS cells and cause infection. As the carbohydrate moieties of salivary mucins serve as attachment sites for bacteria and viruses [14,15], changes in charge or glycosylation pattern as a result of HIV infection could affect the ability of the mucins to aggregate the virus.

The PAS stained 4-20% gradient gel demonstrated that there was a size difference between the mucins from HIV negative and positive individuals as well as between the mucins from HIV patients of different CD4 counts, with the mucins from HIV positive individuals showing slightly more penetration or higher electrophoretic mobility. Again changes in the glycosylation pattern could be implicated. Furthermore, as the degree of glycosylation affects the electrophoretic mobility [16,17], the appearance of the mucins from HIV negative and positive individuals on the gradient gel were different. It should be noted that any population of mucins exhibit polydispersity and even heterogeneity with respect to size, and coupled with their extensive glycosylation, they appear as smears on SDS-PAGE gels and display different electrophoretic mobilities. In summary, as the structural differences in mucins are related to physiologically different functions [18], the size or structural difference of the salivary mucins from HIV patients may affect their ability to trap or aggregate the virus. However, the differences we detected were too small to form any conclusion.

Enzyme linked immunosorbent assay (ELISA) was also performed to determine if the immunoreactivity of the salivary mucins was altered due to the HIV infection. As shown in the result section immunoreactivity differences

between mucins from HIV negative and positive individuals was observed, with both MUC5B and MUC7 mucins from HIV negative individuals showing the highest reactivity. If not for the shortage of antibody, better immunoreactivity difference between MUC7 mucins from HIV negative and positive individuals could have been shown by increasing the concentration of the primary antibody. Although the reason is not clear, as variation in glycosylation can affect antibody binding [17], the HIV infection may have affected the glycosylation pattern of the mucins which could result in epitope modification.

Western blotting has shown varying mobility of MUC5B and especially MUC7 from normals and HIV patients of different CD4 counts on an agarose gel. Mucins of higher charge migrate further into the gel than those of lower charge [19]. The MUC7 from positive patients migrated further than that from normal individuals. Therefore, these diseased species of MUC7 were more highly charged than normal MUC7. If this is due to an altered glycosylation then one can expect shorter side chains and an exposure of more charged groups on the mucin, with a consequent increase in the charge per density ratio of the mucin. It would also be expected that MUC7 from patients with a CD4 count > 400 would migrate closer to where normal MUC7 is positioned. Surprisingly this was not to be the case because it seemed like the mobility of MUC7 from patients with CD4 < 200 (Figure 5, lane 9) migrated less than CD4 200-400 (lane 8) and CD4 > 400 (lane 7). Also the gels could be overloaded and thus we have not highlighted the mobility of the different mucins adequately.

The role of salivary MUC5B and MUC7 in protecting the oral cavity from bacteria, viruses, yeasts, and toxins is well documented [14,20-22]. However, Lal *et al.* [11] reported that compared to HIV negative individuals, saliva from HIV positive individuals possess considerably lower anti-candidal activity. This was supported by the findings of Gururaja *et al.* [23] and Situ *et al.* [24] that fungal infections specifically *Candida albicans* has increasingly colonized the oral cavity of HIV positive patients. This suggested that the HIV infection may have induced functional alteration on the salivary mucins which are very potent in normal circumstances. For instance MUC7 in immunocompromised individuals is reported to lose the expression of sugar receptor (sLe^x) hence making the individual more susceptible to oral diseases [25]. Furthermore, as covalently modified MUC7 is reported to lose its potency against *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Candida albicans* [20], the idea that HIV infection might induce structural changes to the mucins is perhaps a possibility. In summary the SDS-PAGE (gradient gel), ELISA and Western blot analysis strengthens these findings.




Figure 5 Western blotting of salivary MUC5B and MUC7 from HIV positive individuals with different CD4 counts. Lane 1, MUC5B from patients with CD4 > 400, lane 2, MUC5B from patients with CD4 200-400, lane 3, MUC5B from patients with CD4 < 200, lane 4, MUC5B from HIV negative individual, lane 5, crude saliva (positive control), lane 6, MUC7 (negative control), lane 7, MUC7 from patients with CD4 > 400, lane 8, MUC7 from patients with CD4 200-400, lane 9, MUC7 from patients with CD4 < 200, lane 10, MUC7 from HIV negative individuals, lane 11, crude saliva (positive control) and lane 12, MUC5B (negative control) were separated by a 1% agarose gel and transferred to nitrocellulose membrane. Following overnight blocking, the membranes were incubated for 2 h with rabbit anti-MUC5B polyclonal (lanes 1-6) and mouse anti-MUC7 monoclonal (lanes 7-12) antibodies diluted in 5% (m/v) low fat milk powder in TBST at 1 in 2000 (rabbit anti-MUC5B) and 1 in 1000 (mouse anti-MUC7). Membranes were then washed 3 × 5 min with TBST and incubated for 1 h with HRPO linked goat anti-rabbit (lanes 1-6) and goat anti-mouse (lanes 7-12) secondary antibodies diluted in 5% (m/v) low fat milk powder in TBST at dilutions of 1 in 5000 and 1 in 1500 respectively. After another TBST wash (3 × 5 min), bands were detected using an ECL detection kit.

A limitation to this study was that of numbers in terms of patient recruitment, volume of saliva obtained from individual patients and the disruption of clinical services in a busy clinic with limited resources. The yield of MUC5B and MUC7 from a single sample was far too little and saliva samples from ten donors “for each CD4 group” had to be pooled to a final volume of approximately 10.0 ml for each group in this study. A broader study is required for statistical verifiability. The use of different HIV-1 strains in the *in vitro* assay is also necessary.

Conclusions

In summary, irrespective of their CD4 count (< 200, 200-400 and > 400) both MUC5B and MUC7 mucins from HIV patients did not inhibit HIV-1 activity. Size, charge and immunoreactivity differences between the mucins from HIV negative and positive individuals and among the mucins from HIV patients of different CD4 count was observed by gradient gel, ELISA and Western blot.

Methods

Ethics

The University of Cape Town Research and Ethics Committee approved this study (ethics approval number REC REF: 283/2004).

Materials

The CEM SS cells were from AIDS Research and Reference Reagent Programme (Germantown, USA). The p24

antigen kit was from Vironostika HIV-1 Antigen kit Biomérieux (France). Monoclonal mouse anti-MUC7 (EU-MUC7a) was kindly provided by Dallas Swallows (University College London, UK). Polyclonal rabbit anti-MUC5B (LUM5B-2) and goat anti-rabbit horse radish peroxidase (HRPO) linked secondary antibodies were kindly provided by Sara Kirkham (Manchester, UK). Polyclonal goat anti-MUC5B (sc-23024), anti-MUC7 (sc-16918) and rabbit anti-goat HRPO linked secondary antibodies were from Santa Cruz (California). Goat anti-mouse HRPO linked secondary antibody was from Novocastra (Newcastle, UK).

Saliva collection

Saliva was collected from HIV positive female volunteers from the clinic of infectious diseases in Groote Schuur Hospital, Cape Town, South Africa. The production of saliva was stimulated by chewing on parafilm and collected into 10 ml of 6 M GuHCl containing a cocktail of protease inhibitors such as 10 mM EDTA, 5 mM NEM, 1 mM PMSF and 0.1% CHAPS, pH 6.5. Samples were collected into cooled containers on ice and stored at -20°C. Samples were grouped into three categories according to the CD4 counts of the patients, less than 200, between 200 and 400 and greater than 400. The volume of saliva produced by each individual varied. Saliva was pooled in 3 groups according to the CD4 counts, to a final volume of approximately 10.0 ml per group. The patients with CD4 count < 200 had full blown AIDS.

Mucin preparation, purification, identification and analysis

The preparation and purification of salivary mucins was done according to the method described by Habte *et al.* [4]. Briefly, each mucin pool was separated by gel filtration on Sepharose CL-4B and subsequently purified by caesium chloride isopycnic density gradient ultra-centrifugation [26]. Mucins were further analysed by SDS-PAGE [27], identified by Western blotting [28] and amino acid analysis [29,30]. Glycoprotein was estimated by the PAS procedure of [31] and protein according to the method of Lowry *et al.* [32].

Enzyme linked immunosorbent assay

Salivary MUC5B and MUC7 from HIV negative and HIV positive individuals with different CD4 counts (< 200, 200-400 and > 400) were coated (10 µg/ml) in PBS (150 µl per well, overnight at 4°C). Non-specific binding of the antibodies was prevented by blocking the wells with 0.5% BSA-PBS (200 µl, 1 h at 37°C) and the plates were washed three times with PBS-Tween. Serial two-fold dilutions of primary antibodies starting from 8 µg/ml (goat anti-MUC5B) and 12 µg/ml (goat anti-MUC7) were added to the plate in 0.5% BSA-PBS and incubated (100 µl, 2 h at 37°C). The plates were washed three times with PBS-Tween and rabbit anti-goat HRPO-linked secondary antibody (1 in 5000 in 0.5% BSA-PBS) was added to each well and incubated (120 µl, 1 h at 37°C). Following three washes with PBS-Tween, 150 µl of the substrate solution (TMB in 0.15 M citrate-phosphate buffer, pH 5.0) was added to each well and the colour was allowed to develop in the dark against the background of the controls (10-15 min) and the A₄₀₅ of each well was measured in a Titertek ELISA plate reader. As a control, wells were coated with PBS.

Toxicity assay

The toxicity of salivary MUC5B and MUC7 from HIV positive individuals with different CD4 counts (< 200, 200-400 and > 400) to the phytohaemagglutinin (PHA) stimulated CEM SS cells was determined by toxicity assay. Briefly 500 µl of the CEM SS cells in RPMI complete containing 10% Fetal Calf Serum, 1% Penicillin/Streptomycin antibiotic, 10 µmol Fungin and 50 µmol 2-mercaptoethanol (final concentration 2.5 × 10⁶ cells/ml) was incubated with 250 µl of IL-2 and 250 µl (0.9 mg) of MUC5B and MUC7 with different CD4 counts (< 200, 200-400 and > 400) in CO₂ incubator for 24 h. As controls CEM SS cells with IL-2 only and IL-2 without CEM SS cells (blank) were used. After spinning at 200 g for 5 min cells were resuspended in 500 µl of RPMI and live and dead cells were counted using Trypan blue exclusion criteria. The percentage of viable cells was calculated as live cells/total cells × 100.

HIV inhibition assay

The anti-HIV-1 activities of salivary MUC5B and MUC7 from HIV positive individuals were tested in an inhibition assay according to the method of Nagashunmugam *et al.* [33]. Briefly MUC5B and MUC7 with different CD4 counts (< 200, 200-400 and > 400) were dissolved in 0.25% PBS and (500 µl or 0.9 mg each) were mixed with 4 ml of the subtype D HIV-1 supernatant fluid (SNF), at the same titer of virus used in the previous study [4] and incubated for 60 min at 37°C separately. As controls, heat inactivated HIV-1 or HIV-1 plus media (RPMI 1640 with 10% Fetal Calf Serum and IL-2) were used. At the end of the incubation period the mixtures (HIV-1 plus MUC5B from HIV patients with CD4 count < 200), (HIV-1 plus MUC5B from HIV patients with CD4 count between 200 and 400), (HIV-1 plus MUC5B from HIV patients with CD4 count > 400), (HIV-1 plus MUC7 from HIV patients with CD4 count < 200), (HIV-1 plus MUC7 from HIV patients with CD4 count between 200 and 400), (HIV-1 plus MUC7 from HIV patients with CD4 count > 400) and the control (HIV-1 plus media) were filtered through 0.45 µm pore size cellulose acetate filter (25 mm diameter) and both the unfiltered and filtered samples were incubated with the CEM SS cells at 37°C at a concentration of 0.5 × 10⁶ cells/ml for 30 min, 1 h and 3 h. Cells were then washed three times with PBS to remove free virus and cultured. Supernatant fluid was harvested on Day 4 and viral replication was measured by a qualitative p24 antigen assay. Endpoints were calculated by the Reed-Muench formula and the 50% tissue culture infective dose (TCID₅₀) was expressed as the highest dilution that produced a positive qualitative p24 antigen result. All samples were done in triplicate and the anti-HIV-1 activity of each sample was tested in a serial tenfold dilution (10⁻¹ to 10⁻⁴).

Acknowledgements

We thank Prof. Dallas Swallows (University College London, UK) and Dr Sara Kirkham (University of Manchester, UK) for the antibodies and the University of Cape Town Postgraduate Funding Office for financial support. This work was supported by the South African Medical Research Council grant CHM504-415566 and the National Research Foundation of South African GUN number FA2005040800007. Marilyn Tyler and Warda Brown edited the manuscript.

Author details

¹Department of Surgery, Division of General Surgery, University of Cape Town, Observatory, Cape 7925, South Africa. ²Discipline of Medical Virology, University of Stellenbosch and National Health Laboratory Service, Tygerberg, South Africa. ³Department of Paediatric Medicine, University of Cape Town, Observatory, Cape 7925, South Africa.

Authors' contributions

HHH carried out the biochemical experiments and drafted the manuscript. CdB established and oversaw the *in vitro* assay. ZEL helped with the biochemistry experiments. PR gave clinical advice and oversaw sample collection. ASM originated the idea, supervised the project and reviewed the drafts. All authors read and approved the final manuscript

Competing interests

The authors declare that they have no competing interests.

Received: 11 May 2010 Accepted: 14 October 2010

Published: 14 October 2010

References

1. Bergery EJ, Cho MI, Blumberg BM, Hammarskjold ML, Rekosh D, Epstein LG, Levine MJ: **Interaction of HIV-1 and human salivary mucins.** *J Acquir Immune Defic Syndr* 1994, **7**:995-1002.
2. Kennedy S, Davis C, Abrams WR, Billings PC, Nagashunmugam T, Friedman H, Malamud D: **Submandibular salivary proteases: lack of a role in anti-HIV activity.** *J Dent Res* 1998, **77**:1515-1519.
3. Moore BE, Flaitz CM, Coppenhaver DH, Nichols M, Kalmaz GD, Bessman JD, Cloyd MW, Lynch DP, Prabhakar BS, Baron S: **HIV recovery from saliva before and after dental treatment: inhibitors may have critical role in viral inactivation.** *J Am Dent Assoc* 1993, **124**:67-74.
4. Habte HH, Mall AS, de Beer C, Lotz ZE, Kahn D: **The role of crude human saliva and purified salivary MUC5B and MUC7 mucins in the inhibition of Human Immunodeficiency Virus type 1 in an inhibition assay.** *Virology* 2006, **3**:99.
5. Habte HH, de Beer C, Lotz ZE, Tyler MG, Kahn D, Mall AS: **Inhibition of human immunodeficiency virus type 1 activity by purified human breast milk mucin (MUC1) in an inhibition assay.** *Neonatology* 2008, **93**:162-170.
6. Habte HH, de Beer C, Lotz ZE, Tyler MG, Schoeman L, Kahn D, Mall AS: **The inhibition of the Human Immunodeficiency Virus type 1 activity by crude and purified human pregnancy plug mucus and mucins in an inhibition assay.** *Virology* 2008, **5**:59.
7. Habte HH, Kotwal GJ, Lotz ZE, Tyler MG, Abrahams M, Rodrigues J, Kahn D, Mall AS: **Antiviral activity of purified human breast milk mucin.** *Neonatology* 2007, **92**:96-104.
8. Lalloo LB, Laal S, Hoxie JA, Zolla-Pazner S, Bandres JC: **Exclusion of HIV coreceptors CXCR4, CCR5, and CCR3 from the HIV envelope.** *AIDS Res Hum Retroviruses* 1999, **15**:895-897.
9. Nara PL, Hatch WC, Dunlop NM, Robey WG, Arthur LO, Gonda MA, Fischinger PJ: **Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody.** *AIDS Res Hum Retroviruses* 1987, **3**:283-302.
10. Wagner RP, Tian H, McPherson MJ, Latham PS, Orenstein JM: **AIDS-associated infections in salivary glands: autopsy survey of 60 cases.** *Clin Infect Dis* 1996, **22**:369-371.
11. Lal K, Pollock JJ, Santarpia RP 3, Heller HM, Kaufman HW, Fuhrer J, Steigbigel RT: **Pilot study comparing the salivary cationic protein concentrations in healthy adults and AIDS patients: correlation with antifungal activity.** *J Acquir Immune Defic Syndr* 1992, **5**:904-914.
12. Crombie R, Silverstein RL, MacLow C, Pearce SF, Nachman RL, Laurence J: **Identification of a CD36-related thrombospondin 1-binding domain in HIV-1 envelope glycoprotein gp120: relationship to HIV-1-specific inhibitory factors in human saliva.** *J Exp Med* 1998, **187**:25-35.
13. Taylor KL, Mall AS, Barnard RA, Ho SB, Cruse JP: **Immunohistochemical detection of gastric mucin in normal and disease states.** *Oncol Res* 1998, **10**:465-473.
14. Bosch JA, de Geus EJ, Ligtenberg TJ, Nazmi K, Veerman EC, Hoogstraten J, Amerongen AV: **Salivary MUC5B-mediated adherence (ex vivo) of Helicobacter pylori during acute stress.** *Psychosom Med* 2000, **62**:40-49.
15. Prakobphol A, Tangemann K, Rosen SD, Hoover CI, Leffler H, Fisher SJ: **Separate oligosaccharide determinants mediate interactions of the low-molecular-weight salivary mucin with neutrophils and bacteria.** *Biochemistry* 1999, **38**:6817-6825.
16. Pallesen LT, Andersen MH, Nielsen RL, Berglund L, Petersen TE, Rasmussen LK, Rasmussen JT: **Purification of MUC1 from bovine milk-fat globules and characterization of a corresponding full-length cDNA clone.** *J Dairy Sci* 2001, **84**:2591-2598.
17. Patton S, Gendler SJ, Spicer AP: **The epithelial mucin, MUC1, of milk, mammary gland and other tissues.** *Biochim Biophys Acta* 1995, **1241**:407-423.
18. Bolscher J, Veerman E, Van Nieuw Amerongen A, Tulp A, Verwoerd D: **Distinct populations of high-M(r) mucins secreted by different human salivary glands discriminated by density-gradient electrophoresis.** *Biochem J* 1995, **309**(Pt 3):801-806.
19. Thornton CW, Corbett C, Brown R: **HIV infection in adults: a therapeutic update.** *Am J Manag Care* 1999, **5**:1047-1060, quiz 1061-1043.
20. Liu B, Rayment S, Oppenheim FG, Troxler RF: **Isolation of human salivary mucin MG2 by a novel method and characterization of its interactions with oral bacteria.** *Arch Biochem Biophys* 1999, **364**:286-293.
21. Prakobphol A, Boren T, Ma W, Zhixiang P, Fisher SJ: **Highly glycosylated human salivary molecules present oligosaccharides that mediate adhesion of leukocytes and Helicobacter pylori.** *Biochemistry* 2005, **44**:2216-2224.
22. Situ H, Bobek LA: **In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1.** *Antimicrob Agents Chemother* 2000, **44**:1485-1493.
23. Gururaja TL, Levine JH, Tran DT, Naganagowda GA, Ramalingam K, Ramasubbu N, Levine MJ: **Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)1.** *Biochim Biophys Acta* 1999, **1431**:107-119.
24. Situ H, Wei G, Smith CJ, Mashhoon S, Bobek LA: **Human salivary MUC7 mucin peptides: effect of size, charge and cysteine residues on antifungal activity.** *Biochem J* 2003, **375**:175-182.
25. Prakobphol A, Thomsson KA, Hansson GC, Rosen SD, Singer MS, Phillips NJ, Medzhradzsky KF, Burlingame AL, Leffler H, Fisher SJ: **Human low-molecular-weight salivary mucin expresses the sialyl lewisx determinant and has L-selectin ligand activity.** *Biochemistry* 1998, **37**:4916-4927.
26. Creeth JM, Denborough MA: **Density gradient equilibrium methods applied to blood-group specific glycoproteins.** *FEBS Lett* 1970, **6**:117-120.
27. Laemmli UK: **Cleavage of structural proteins during the assembly of the head of bacteriophage T4.** *Nature* 1970, **227**:680-685.
28. Thornton DJ, Howard M, Devine PL, Sheehan JK: **Methods for separation and deglycosylation of mucin subunits.** *Anal Biochem* 1995, **227**:162-167.
29. Klapper D: **A new low-cost, fully automated amino acid analyzer; in Elzinga M (ed): Methods in Protein Sequence Analysis.** Clifton, Humana Press 1982, 509-517.
30. Cohen A, Strydom D: **Amino acid analysis utilizing phenylisothiocyanate derivatives.** *Anal Biochem* 1988, **174**:1-16.
31. Mantle M, Allen A: **A colorimetric assay for glycoproteins based on the periodic acid/Schiff stain [proceedings].** *Biochem Soc Trans* 1978, **6**:607-609.
32. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ: **Protein measurement with the Folin phenol reagent.** *J Biol Chem* 1951, **193**:265-275.
33. Nagashunmugam T, Friedman HM, Davis C, Kennedy S, Goldstein LT, Malamud D: **Human submandibular saliva specifically inhibits HIV type 1.** *AIDS Res Hum Retroviruses* 1997, **13**:371-376.

doi:10.1186/1743-422X-7-269

Cite this article as: Habte et al.: Anti-HIV-1 activity of salivary MUC5B and MUC7 mucins from HIV patients with different CD4 counts. *Virology Journal* 2010 **7**:269.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

